Has Tingting Li, MD received payments from drug or device companies?

Yes. Drug and device makers reported $130,037 in general payments to Tingting Li, MD across 131 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tingting Li, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tingting Li, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tingting Li, MD

Nephrology · Saint Louis, MONPI 1831154053

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $106,019 of the $130,037 with a category attached, or 81.5%. 8 manufacturers reported payments, led by Novartis at 35.8% of the total. 2025 is the largest year on record at $60,993, more than ten times the $3,680 reported in 2020. Among nephrology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$130,037in general payments, 2019–2025

Across 131 payments — averaging $992.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$47K
Travere Therapeutics, Inc.$30K
GSK$29K
Calliditas Therapeutics US Inc.$12K
Amgen$7K
Aurinia Pharma U.S., Inc.$5K
plus $222 from 2 others

$240,180in research payments, 2019–2025

Across 37 payments — averaging $6491.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$66K
Calliditas Therapeutics US Inc.$58K
Genentech, Inc.$35K
Pfizer$29K
E.r. Squibb & Sons, L.L.C.$20K
Novartis$11K
plus $21K from 3 others

What the payments were for

Consulting fees$106,01982%
Speaking & faculty fees$8,3406%
Travel & lodging$10,6088%
Food & beverage$5,0684%
Education$30%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	27	$46,558
Travere Therapeutics, Inc.	48	$30,335
GSK	25	$28,930
Calliditas Therapeutics US Inc.	11	$12,146
Amgen	9	$6,521
Aurinia Pharma U.S., Inc.	9	$5,325
Apellis Pharmaceuticals, Inc.	1	$139
Vertex	1	$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BENLYSTA$21,742
Fabhalta$20,657
TARPEYO$12,116
Tavneos$6,446
LUPKYNIS$5,130
Filspari$963

How this compares

$130,037 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri →

Medicare billing

Part B allowed, 2024

$152,102

Medicare patients

212

Services billed

827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XphozahTenapanor Hcl	14	$73,484
VelphoroSucroferric Oxyhydroxide	13	$34,273
FarxigaDapagliflozin Propanediol	23	$29,218
JardianceEmpagliflozin	36	$26,779
AuryxiaFerric Citrate	13	$19,307
Sevelamer Carbonate	58	$8,812
Calcium Acetate	14	$1,167
Mycophenolate Mofetil	12	$832
Bumetanide	14	$690
Amlodipine Besylate	129	$626
Losartan Potassium	91	$497
Calcitriol	20	$445
Furosemide	82	$433
Midodrine Hcl	13	$368
Metoprolol Succinate	35	$360

Paid to pharmacies, not to this prescriber.

Other nephrology in Saint Louis

Marcos RothsteinSaint Louis$350K
Anuja JavaSaint Louis$240K
Daniel CoyneSaint Louis$163K
Tarek AlhamadSaint Louis$155K
Krista LentineSaint Louis$86K
Rowena Delos SantosSaint Louis$30K
Kabeya MwintshiSaint Louis$25K
Naoka MurakamiSaint Louis$24K
Benjamin HumphreysSaint Louis$13K
Leslie GewinSaint Louis$12K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →